title: Phase I clinical and pharmacokinetic study of bi-weekly carboplatin/paclitaxel chemotherapy in elderly patients with advanced non-small cell lung cancer.
abstract: OBJECTIVE
  We evaluated the pharmacokinetics and quality of life of elderly patients with advanced non-small-cell lung cancer (NSCLC) treated with bi-weekly carboplatin and paclitaxel chemotherapy, and determined the maximum tolerated dose (MTD) of this treatment.
  
  
  METHODS
  Eligible patients had histologically- or cytologically-proven inoperable NSCLC, age of 70 years or older, no prior treatment, and Eastern Cooperative Oncology Group performance status 0-2. Paclitaxel was administered in combination with carboplatin under a bi-weekly schedule. We determined the plasma concentrations of both drugs during therapy.
  
  
  RESULTS
  The median patient age was 80 years. Using carboplatin at AUC 3, the MTD of paclitaxel was 100 mg/m(2). Both hematological and non-hematological toxicities were mostly mild and manageable. Although paclitaxel is predominantly metabolized in the liver, clearance was decreased in patients with lower estimated glomerular filtration rate.
  
  
  CONCLUSIONS
  Bi-weekly treatment, as described here, is feasible for elderly patients as a conventional regimen, particularly in the outpatient setting, due to its lower toxicity.
authors.affiliation: Department of Internal Medicine, Division of Medical Oncology & Respiratory Medicine, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane 693-8501, Japan.
authors.forename: Yukari
authors.initials: Y
authors.lastname: Tsubata
authors.forename: Tamio
authors.initials: T
authors.lastname: Okimoto
authors.forename: Kiyotaka
authors.initials: K
authors.lastname: Miura
authors.forename: Fumi
authors.initials: F
authors.lastname: Karino
authors.forename: Shinichi
authors.initials: S
authors.lastname: Iwamoto
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Tada
authors.forename: Takeshi
authors.initials: T
authors.lastname: Honda
authors.forename: Shunichi
authors.initials: S
authors.lastname: Hamaguchi
authors.forename: Miki
authors.initials: M
authors.lastname: Ohe
authors.forename: Akihisa
authors.initials: A
authors.lastname: Sutani
authors.forename: Takashige
authors.initials: T
authors.lastname: Kuraki
authors.forename: Akinobu
authors.initials: A
authors.lastname: Hamada
authors.forename: Takeshi
authors.initials: T
authors.lastname: Isobe
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D016190:Carboplatin / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D011788:Quality of Life
chemical_list: D016190:Carboplatin; D017239:Paclitaxel